

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO OR FROM THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA (THE "UNITED STATES" OR THE "US")) AUSTRALIA, NEW ZEALAND, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, REPUBLIC OF IRELAND, SINGAPORE, HONG KONG OR JAPAN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER, SOLICITATION OR SALE OF SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"), AND IS DISCLOSED IN ACCORDANCE WITH THE COMPANY'S OBLIGATIONS UNDER ARTICLE 17 OF MAR. IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION (AS PERMITTED BY UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

16 May 2025

Solonis Therapeutics plc
("SOLONIS" or the "Company")

Result of Bookbuild

Solonis Therapeutics plc (LSE: SVNS), an innovative biotechnology company co-developing therapeutics for mental health disorders, is pleased to announce that, further to the Company's announcement on 15 May 2025 (the "Fundraise Launch Announcement"), the Company has conditionally raised gross proceeds of approximately £2.0 million (the "Fundraise") through the proposed issue of 1,538,461,529 new ordinary shares of £0.001 each in the Company (the "Fundraise Shares") with certain existing and new institutional and other investors at the Issue Price of 0.13 pence per Fundraise Share.

The Fundraise Shares, in aggregate, represent approximately 67.01 per cent of the issued share capital of the Company prior to the Fundraise.

Allenby Capital Limited ("Allenby") and Singer Capital Markets Securities Limited ("Singer") acted as joint brokers and joint bookrunners in respect of the Fundraise.

Admission and Total Voting Rights

Application will be made for the 3,612,840,057 Fundraise Shares and Consideration Shares, as defined in the Fundraise Launch Announcement (together the "New Ordinary Shares"), to be admitted to trading on the Main Market of the London Stock Exchange and to listing in the FCA's Official List Equity Shares (transition) category ("Admission").

It is expected that Admission will become effective and that dealings in the New Ordinary Shares will commence at 8.00 a.m. on 27 May 2025. The issue and allotment of the Fundraise Shares is conditional upon, *inter alia*, Admission becoming effective and the placing agreement entered into between the Company, Allenby and Singer (the "Placing Agreement") not being terminated in accordance with its terms.

Following Admission, the Company's enlarged issued ordinary share capital will comprise 5,908,770,690 ordinary shares. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Director Participations

The Company is undertaking material related party transactions with Nicholas Nelson (Non-Executive Director), Dennis Purcell (Non-Executive Chairman) (together the "Participating Directors") and Ryan Neates (a PDMR) in relation to their participation in the Fundraise for the purpose of rule 7.3 of the FCA's Disclosure Guidance and Transparency Rules, as further detailed below:

- a) Nicholas Nelson will acquire 38,461,538 Fundraise Shares at the Issue Price;
- b) Dennis Purcell will acquire 38,461,538 Fundraise Shares at the Issue Price; and
- c) Ryan Neates, the non-board finance director of the Company, will acquire 3,846,153 Fundraise Shares at the Issue Price.

These material related party transactions have been approved by the board of directors of the Company. The Participating Directors did not take part in the board of directors' consideration of the transactions with them and they did not vote on the relevant board decision.

Directors' shareholdings on Admission

Name	Role	New Ordinary Shares being subscribed for	New Ordinary Shares to be issued pursuant to Awakn Acquisition	Shareholding on Admission	% of enlarged issued share capital on Admission
Nicholas Nelson	Non-Executive Director	38,461,538	-	205,961,538	3.49%

Dennis Purcell	Chair	38,461,538	1,400,100	39,861,638	0.67%
Anthony Tennyson	Chief Executive Officer	-	108,400,689	108,400,689	1.83%
Dr Renata Crome	Non-Executive Director	-	-	-	-
Ryan Neates*	Finance Director	3,846,153	-	3,846,153	0.07%

*non-board PDMR

Defined terms used in the Fundraise Launch Announcement have the same meanings when used in this announcement.

This announcement should be read in its entirety. In particular, you should read and understand the information provided in the "Important Notices" section below.

Enquiries:

Solvonis Therapeutics plc anthony@solvonis.com

Anthony Tennyson, CEO & Executive Director

Allenby Capital Limited (Financial Adviser and Joint Broker) [+44 \(0\) 20 3328 5656](tel:+442033285656)

Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)
Guy McDougall (Sales & Corporate Broking)

Singer Capital Markets Limited (Joint Broker) [+44\(0\) 20 7496 3000](tel:+442074963000)

Phil Davies/Patrick Weaver

Director/PDMR MAR disclosures

The following notification, made in accordance with the requirements of the UK Market Abuse Regulation, gives further details.

1 Details of the person discharging managerial responsibilities / person closely associated																
a)	Name	<table border="1"> <thead> <tr> <th>Name</th><th>Position</th></tr> </thead> <tbody> <tr> <td>Nicholas Nelson</td><td>Non-Executive Director</td></tr> <tr> <td>Dennis Purcell</td><td>Chair</td></tr> <tr> <td>Anthony Tennyson</td><td>Chief Executive Officer</td></tr> <tr> <td>Ryan Neates</td><td>Finance Director</td></tr> </tbody> </table>					Name	Position	Nicholas Nelson	Non-Executive Director	Dennis Purcell	Chair	Anthony Tennyson	Chief Executive Officer	Ryan Neates	Finance Director
Name	Position															
Nicholas Nelson	Non-Executive Director															
Dennis Purcell	Chair															
Anthony Tennyson	Chief Executive Officer															
Ryan Neates	Finance Director															
2	Reason for the notification															
a)	Position/status	See above														
b)	Initial notification /Amendment	Initial notification														
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor															
a)	Name	Solvonis Therapeutics Plc														
b)	LEI	2138005PH70JRCRPUD88														
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted															
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of £0.001 each in Solvonis Therapeutics Plc Identification code (ISIN) for Solvonis Therapeutics Plc ordinary shares: GB00BMD1Z199														
b)	Nature of the transaction	Issue of consideration shares														
c)	Price(s) and volume(s)	Name	Price(s)	Volume(s)												
		Nicholas Nelson	0.13p	38,461,538												
		Dennis Purcell	0.13p	39,861,638												
		Anthony Tennyson	0.13p	108,400,689												
		Ryan Neates	0.13p	3,846,153												
d)	Aggregated information: - Aggregated volume - Price	N/A														
e)	Date of the transaction	15 May 2025														
f)	Place of the transaction	London Stock Exchange, XLON														

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROIGPURPAUPAUQQ